Bausch Health Appeals Anticipated Court Decision Regarding Xifaxane Patents
Yesterday, Bausch Health Companies Inc BHC The stock closed 50% lower following reports of the Xifaxan (rifaximin) patent litigation resolution. The company’s shares gained slightly